Enovis Corporation
NYSE:ENOVMedical - Devices
+$0.73 today
- Market cap
- $1.56B
- Beta
- 1.49
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$20.02
Volume 0.88M
Average 0.99M
ENOV Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Enovis CorporationNYSE: ENOV
Selling, General & Admin · Q1 FY2026 · quarter ended Apr 2026
Selling, general & admin grows in line with its trailing trend
Q1 FY2026 selling, general & admin of $271.78M rose 1.0% year over year, behind the +1.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 0.5% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Selling, general & admin amounted to 47.6% of revenue in FY2025, up 3.0 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 9 analysts of $1.11B (+3.5%) for the fiscal year ending Dec 2026, a slowdown from the +13.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterApr 2026
- $271.78M+0.5% QoQ
- Last fiscal yearDec 2025
- $1.07B+13.9% YoY
- LTMApr 2026
- $1.06B+1.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1.0% | +3.2% | +2.2 pp |
| 1 year | +13.9% | +3.5% | -10.5 pp |
| 3-year CAGR | +11.5% | +4.3% | -7.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.07B USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +12.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.07B | +13.9% |
| FY2024 | 2024-12-31 | 939.36M | +13.1% |
| FY2023 | 2023-12-31 | 830.31M | +7.4% |
| FY2022 | 2022-12-31 | 772.91M | +16.1% |
| FY2021 | 2021-12-31 | 665.78M | — |
Selling, General & Admin vs competitors
How ENOV compares with its peers on the latest reported figures
- ENOV's LTM Apr 2026 selling, general & admin of $1.06B is the highest of the 16 companies compared; the peer median is $320.88M.
- Its year-over-year change of +1.6% is the 10th highest of 16, against a peer median of +6.0%.
- Selling, general & admin amounts to 46.4% of revenue for ENOV, versus a peer median of 21.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $1.06B | +1.6% | +11.5% | 46.4% | |
| LTM Jun 2026 | $848.2M | +12.7% | +8.1% | 23.7% | |
| LTM Jun 2026 | $786.9M | +19.3% | +14.5% | 29.4% | |
| LTM Jul 2026 | $750.91M | -3.0% | -6.0% | 21.1% | |
| LTM Jul 2026 | $698.5M | +30.7% | +16.9% | 14.7% | |
| LTM Jul 2026 | $679.2M | +6.0% | +4.1% | 17.5% | |
| LTM Sep 2026 | $511.14M | +7.3% | +3.1% | 22.6% | |
| LTM Jun 2026 | $342.6M | +12.8% | +4.6% | 28.0% | |
| LTM Jul 2026 | $320.88M | +12.7% | +10.4% | 27.9% | |
| LTM Feb 2026 | $168.32M | -0.6% | -8.4% | 26.9% | |
| LTM Jul 2026 | $113.1M | -16.3% | +3.5% | 12.7% | |
| LTM Jun 2026 | $104.19M | +2.3% | +6.9% | 14.8% | |
| LTM Mar 2026 | $47.9M | -2.4% | +4.4% | 12.9% | |
| LTM Apr 2026 | $44.21M | -0.3% | -5.8% | 24.3% | |
| LTM Mar 2026 | $41.56M | +11.9% | +21.7% | 16.9% | |
| LTM Mar 2026 | $370K | -99.0% | -4.5% | 0.4% | |
| Peer median (excluding ENOV) | $320.88M | +6.0% | +4.4% | 21.1% | |
Competitors are the stored peer set for ENOV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.43B | 1.56B | 1.71B | 2.11B | 2.25B |
| Cost of Revenue | 648.51M | 693.72M | 716.42M | 926.87M | 902.79M |
| Gross Profit | 777.68M | 869.38M | 990.78M | 1.18B | 1.35B |
| Gross Margin | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Research & Development | 49.09M | 60.83M | 75.33M | 91.3M | 120.33M |
| Selling, General & Admin | 665.78M | 772.91M | 830.31M | 939.36M | 1.07B |
| Operating Expenses | 840.47M | 940.56M | 1.06B | 1.96B | 1.36B |
| Depreciation & Amortization | 262.92M | 219.71M | 217.11M | 284.8M | 294.38M |
| EBITDA | 170.25M | 241.69M | 169.73M | (481.03M) | (830.22M) |
| EBITDA Margin | 11.9% | 15.5% | 9.9% | -22.8% | -36.9% |
| Operating Income | (62.8M) | (71.18M) | (65.71M) | (775.72M) | (18.87M) |
| Operating Margin | -4.4% | -4.6% | -3.8% | -36.8% | -0.8% |
| Interest Income | 0 | 200K | 0 | 0 | 0 |
| Interest Expense | 29.11M | 24.95M | 19.75M | 57.1M | 34.82M |
| Other Income / Expenses | (58.98M) | 69.11M | (1.42M) | (47.21M) | (1.14B) |
| Income Before Tax | (121.78M) | (2.07M) | (67.13M) | (822.92M) | (1.16B) |
| Pre-Tax Margin | -8.5% | -0.1% | -3.9% | -39.0% | -51.6% |
| Income Tax Expense | (19.53M) | 36.12M | (13.29M) | 4.49M | 22.29M |
| Net Income | 71.66M | (13.29M) | (33.26M) | (825.49M) | (1.18B) |
| Net Margin | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
| EPS (Basic) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| EPS (Diluted) | (2.02) | (0.28) | (0.61) | (14.93) | (20.86) |
| Weighted Avg Shares | 51.14M | 54.07M | 54.53M | 55.28M | 56.79M |
| Weighted Avg Shares (Diluted) | 51.14M | 54.07M | 54.49M | 55.28M | 56.79M |
Enovis Corporation
NYSE:ENOV
Intrinsic Alpha fair value
Locked
Current Price
$27.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.